Biobehavioral Changes Following Transition to Automated Insulin Delivery: A Large Real-life Database Analysis
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To document glycemic and user-initiated bolus changes following transition from predictive low glucose suspend (PLGS) system to automated insulin delivery (AID) system during real-life use. RESEARCH DESIGN AND METHODS: We conducted analysis of 2,329,166 days (6,381 patient-years) of continuous glucose monitoring (CGM) and insulin therapy data for 19,354 individuals with type 1 Diabetes, during 1-month PLGS use (Basal-IQ technology) followed by 3-month AID use (Control-IQ technology). Baseline characteristics are as follows: 55.4% female, age (median/quartiles/range) 39/19–58/1–92 years, mean ± SD glucose management indicator (GMI) 7.5 ± 0.8. Primary outcome was time in target range (TIR) (70–180 mg/dL). Secondary outcomes included CGM-based glycemic control metrics and frequency of user-initiated boluses. RESULTS: Compared with PLGS, AID increased TIR on average from 58.4 to 70.5%. GMI and percent time above and below target range improved as well: from 7.5 to 7.1, 39.9 to 28.1%, and 1.66 to 1.46%, respectively; all P values <0.0001. Stratification of outcomes by age and baseline GMI revealed clinically significant differences. Glycemic improvements were most pronounced in those <18 years old (TIR improvement 14.0 percentage points) and those with baseline GMI >8.0 (TIR improvement 13.2 percentage points). User-initiated correction boluses decreased from 2.7 to 1.8 per day, while user-initiated meal boluses remained stable at 3.6 to 3.8 per day. CONCLUSIONS: Observed in real life of >19,000 individuals with type 1 diabetes, transitions from PLGS to AID resulted in improvement of all glycemic parameters, equivalent to improvements observed in randomized clinical trials, and reduced user-initiated boluses. However, glycemic and behavioral changes with AID use may differ greatly across different demographic and clinical groups.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two publications of real-life data, one reporting 9300 users for a year 136 and the other 21,000 users for four months, 137 confirmed that the system performance in real life is virtually identical to its performance in the pivotal clinical trials.[132][133][134]136,137”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“Similar analyses were conducted for all other secondary CGM-based and insulin delivery–based outcomes, which included the metrics recommended by the International Consensus on Time in Range (25): time <54 and <70 mg/dL, time >180 and >250 mg/dL, coefficient of variation, total daily insulin, and the number of user-ini…”
MethodSelf-citationSix-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationGlucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684 · cited 3×
“Note that the GMI is a unit-less linear function of average glucose, presented sometimes as a percentage because of its clinical analogy with HbA1c (24).”
BackgroundMethodInfluentialSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“Two AID systems, the Medtronic MiniMed 670G/770G (8) and Tandem Diabetes Care t:slim X2 pump with Control-IQ technology (9,10), have U.”
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
Breton, M. D., Kanapka, L. G., Beck, R. W., Ekhlaspour, L., Forlenza, G. P., Cengiz, E., Schoelwer, M., Ruedy, K. J., Jost, E., Carria, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004736 · Cited by 455
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Brown, S. A., Forlenza, G. P., Bode, B. W., Pinsker, J. E., Levy, C. J., Criego, A. B., Hansen, D. W., Hirsch, I. B., Carlson, A. L., Bergenstal, R. M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0172 · Cited by 286
Cited by
Beck, R. W., Kanapka, L. G., Breton, M. D., Brown, S. A., Wadwa, R. P., Buckingham, B. A., Kollman, C., & Kovatchev, B. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0558 · Cited by 111
“These findings are consistent with the real-world data reported by Kovatchev et al. 13 Despite performing fewer user-initiated boluses, participants with high baseline HbA1c levels showed the largest improvement in HbA1c compared with the Control group; in participants with baseline HbA1c ‡ 8.5%,…”
InfluentialSelf-citationForlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
Real-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
“39,40 The majority of AID system studies included < 100 users, 39,41–51 yet 6 articles encompassed data from > 3000 users 40,52–56 and 3 reports had > 10,000 users.”
InfluentialRenard, E., Joubert, M., Villard, O., Dreves, B., Reznik, Y., Farret, A., Place, J., Breton, M. D., Kovatchev, B. P., & iDCL Trial Research Group (2023) · Diabetes Care · doi:10.2337/dc23-0685 · Cited by 51
Self-citationKovatchev, B. P., Colmegna, P. H., Pavan, J., C., J. L. D., Villa-Tamayo, M. F., Koravi, C. L. K., Santini, G., Alix, C., Stumpf, M. M., & Brown, S. A. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01679-y · Cited by 64
“Nevertheless, it is evident that, with the expected low incidence of hypoglycaemia in this population 1,13 , ABC effectively and safely reduced exposure to hyperglycaemia.”
InfluentialSelf-citationDeveloping the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
Self-citationReal‐world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta‐analysis
Yang, Q., Zeng, B., Hao, J., Yang, Q., & Sun, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15718 · Cited by 46
Kovatchev, B. P., Castillo, A., Pryor, E. C., Kollar, L. L., Barnett, C. L., DeBoer, M. D., Brown, S. A., & for the NAP Study Team (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0469 · Cited by 46
“41 But, integrated AID devices that do not rely on external computing resources, for example, Medtronic’s AHCL, 22,23 Tandem’s Control-IQ, 1,2,4,7 and Insulet’s Omnipod 5, 42 cannot afford running complex non-linear algorithms.”
Self-citationUse of diabetes technology in children
Schoelwer, M. J., DeBoer, M. D., & Breton, M. D. (2024) · Diabetologia · doi:10.1007/s00125-024-06218-0 · Cited by 33
“Missed or late meal announcements are common in older children and adolescents and might occur more often in adolescents on AID as users learn that the system will compensate by increasing the insulin delivery in response to postprandial hyperglycaemia [29–31].”
BackgroundClosed-Loop Control, Artificial Intelligence–Based Decision-Support Systems, and Data Science
Nimri, R., Phillip, M., Clements, M. A., & Kovatchev, B. P. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.2505 · Cited by 26
“And several studies reported real-life data for various AID systems (28–35), with one study reporting data for nearly 20,000 AID users (28).”
Self-citationLaugesen, C., Ritschel, T., Ranjan, A. G., Hsu, L. J., Jørgensen, J. B., Svensson, J., Ekhlaspour, L., Buckingham, B. A., & Nørgaard, K. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0022 · Cited by 25
Laesser, C. I., Piazza, C. D., Schorno, N., Nick, F., Kastrati, L., Züger, T., Barnard-Kelly, K. D., Wilinska, M. E., Nakas, C. T., Hovorka, R., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06319-w · Cited by 31
Pöhlmann, J., Smith‐Palmer, J., Serné, E. H., Tuomaala, A., JENDLE, J. H., Choudhary, P., Bosi, E., Mohan, V., van den Heuvel, T. R. A., Cohen, O., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70161 · Cited by 23
Closed-Loop and Artificial Intelligence–Based Decision Support Systems
Nimri, R., Phillip, M., & Kovatchev, B. P. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.2505 · Cited by 22
Self-citationC., J. L. D., Colmegna, P. H., & Breton, M. D. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0468 · Cited by 15
“17 This indicates a potential for improvement and also highlights the compromise imposed by current insulin analogs.”
Singh, R., Imberg, H., Ahmadi, S. S., Hallström, S., JENDLE, J. H., Tengmark, B.-O., Folino, A., Marie, E., & Lind, M. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241242386 · Cited by 17
“26 On a larger scope, safety data of the TCIQ and M780 systems in real-world settings are sparse highlighting the need for further studies.”
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems
Jacobs, P. G., Levy, C. J., Brown, S. A., Riddell, M. C., Çınar, A., Boughton, C. K., Breton, M. D., Dassau, E., Forlenza, G. P., Henderson, R. J., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251338754 · Cited by 24
Real-Life Use of Automated Insulin Delivery in Individuals With Type 2 Diabetes
Fabris, C., & Kovatchev, B. P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241274786 · Cited by 11
Self-citationBarnard-Kelly, K. D., Gonder-Frederick, L. A., Weissberg-Benchell, J. A., & Wisk, L. E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241276550 · Cited by 12
“49 For those individuals whose average number of daily self-administered meal and correction boluses stayed consistent with pre-AID use, average time in range achieved was 84%.”
Self-citationZhou, Y., Boucsein, A., Michaels, V. R., Gray, M. K., Jefferies, C., Wiltshire, E. J., Paul, R. G., Parry‐Strong, A., Pasha, M., Petrovski, G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16210 · Cited by 11
“32,33 However, another key finding in this analysis is that for these young individuals with prior elevated glycaemia, carbohydrate quantity entered and meal announcement frequency only provided modest benefits to glycaemia even with announcement frequency 1/day.”
Kovatchev, B. P., & Lobo, B. J. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0117 · Cited by 10
Self-citationLiarakos, A. L., Crabtree, T. S. J., Griffin, T. P., Hussain, S., Gallen, G., Elliott, J., Furlong, N. J., Narendran, P., Thabit, H., Leelarathna, L., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0165 · Cited by 12
“Our analysis showed lower TIR at follow-up, compared with other HCL studies in real-life clinical settings, 22,26,27 which is explained by the much lower baseline TIR (33.7”
InfluentialEvolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems
Bergenstal, R. M., Heller, A., Breton, M. D., Vigersky, R. A., Brown, S. A., Forlenza, G. P., Sherr, J. L., Hovorka, R., Russell, S. J., Damiano, E. R., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251342239 · Cited by 10
Renard, É., Tubiana‐Rufi, N., Chaillous, L., Bonnemaison, É., Hanaire, H. P., Bismuth, É., Joubert, M., Coutant, R., Schaepelynck, P., Beltrand, J., et al. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.04.002 · Cited by 13
Lindkvist, E. B., Ranjan, A. G., Nørgaard, K., & Svensson, J. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0068 · Cited by 6
Hussain, S., Saltik, A. Z. O., Yu, J. J., de Portu, S., Pollock, R. F., Pöhlmann, J., & Cohen, O. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251380593 · Cited by 8
“6,8,18,23,25,47 A system ’ s ability to improve TIR beyond consensus targets, that is, reduce time spent in dysglycemia as much as possible over PwT1D ’ s lifetimes, can help inform PwT1D, clinician, and commissioning decision-making, along with criteria such as system usability, costs, and patient…”
Smartphone Bolus Feature Increases Number of Insulin Boluses in People With Low Bolus Frequency
Messer, L. H., D’Souza, E. W., Merchant, G., Müeller, L., Farnan, J., HABIF, S., & Pinsker, J. E. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231191796 · Cited by 6
Adaptive Biobehavioral Control: A Pilot Analysis of Human–Machine Coadaptation in Type 1 Diabetes
Colmegna, P. H., McFadden, R. K., Fabris, C., Lobo, B. J., Nass, R. M., Oliveri, M. C., Brown, S. A., & Kovatchev, B. P. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0399 · Cited by 6
Self-citationvan den Heuvel, T. R. A., Castañeda, J., Thijs, I., Arrieta, A., LINTEREUR, L. J., Shin, J., & Cohen, O. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0121 · Cited by 6
Artificial Intelligence in Diabetes Care
Dubský, M., Liegertová, M., Bém, R., Sojáková, D., Fejfarová, V., & Jude, E. B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70720 · Cited by 6
Papa, G. F. S., Cannarella, R., Gusmano, C., Finocchiaro, C., Anzaldi, M., Gruttadauria, G., Patti, L., Presti, D. L., Calabrisotto, S. S., Condorelli, R. A., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112476 · Cited by 5
Wang, Q., Li, X., Zhang, W., Wang, H., Tang, J., Ding, Y., Zheng, X., & Luo, S. (2025) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188251350210 · Cited by 4
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems
Jacobs, P. G., Levy, C. J., Brown, S. A., Riddell, M. C., Çınar, A., Boughton, C. K., Breton, M. D., Dassau, E., Forlenza, G. P., Henderson, R. J., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0129 · Cited by 7
Evolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems
Bergenstal, R. M., Heller, A., Breton, M. D., Vigersky, R. A., Brown, S. A., Forlenza, G. P., Sherr, J. L., Hovorka, R., Russell, S. J., Damiano, E. R., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18801.rmb · Cited by 6
Wu, Z., Talbo, M. K., Lebbar, M., Messier, V., Courchesne, A., Brazeau, A., & RABASA-LHORET, R. P. R. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111006 · Cited by 5
Buckingham, B. A., & Bergenstal, R. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0505 · Cited by 4
Aktürk, H. K., Johnson, A. K., Welsh, J. B., & Messer, L. H. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251330308 · Cited by 3
Sawyer, A., Forlenza, G. P., & Wadwa, R. P. (2025) · Expert Review of Medical Devices · doi:10.1080/17434440.2025.2585061 · Cited by 2
Artificial Pancreas: The First 20 Years
Doyle, F. J., & Kovatchev, B. P. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251330920 · Cited by 5
Self-citationChatty, P., Gera, S., Rearson, A., Mountain, J. N., Alicea-Trelles, N., Gallop, R., & Marks, B. E. (2025) · Diabetes Care · doi:10.2337/dc25-2082 · Cited by 1
Šantová, A., Plachý, L., Neuman, V., Amaratunga, S. A., Slavenko, M. G., Obermannová, B., Drnkova, L., Průhová, Š., & Šumník, Z. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251415187 · Cited by 1
“21 A recent study analyzing glycemic pro fi les of 189 CwD over 1 month of insulin pump and CGM data further underscored the detrimental impact of missed meal boluses, reporting a 9.7% decrease in TIR for each missed or delayed bolus per day.”
InfluentialRecent Advances in the Management of Type 1 Diabetes in Children
Beck, N. L. (2026) · Advances in Pediatrics · doi:10.1016/j.yapd.2025.12.012 · Cited by 1
HOOVEN-DAVIS, J. T., Libman, I. M., Rothenberger, S. D., & March, C. A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261451670 · Cited by 1
“54 While we found a signi fi cant decrease in bolus frequency from baseline to 3 months, self-initiated bolus entry was similar and stable between CIQ and OP5 users at later follow-up.”
Modestino, M. R., Luca, M. D., Fortuna, U. D., Ferrentino, L., Iacono, O., Verdoliva, R., Foglia, A., & Guardasole, V. (2026) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2026.05.004 · Cited by 1
Artificial Pancreas: The First 20 Years*
Doyle, F. J., & Kovatchev, B. P. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0134 · Cited by 4
Self-citationFrom variability to predictability: why human factors still matter in automated insulin delivery
Hashmi, L., & Hayat, S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112998
First Use of Control-IQ+ Technology in Newly Indicated Populations
Assadi, K. Z., D’Souza, E. W., Pinsker, J. E., & Messer, L. H. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261456818
Automated Insulin Delivery Systems in Youth with Diabetes
Mroweh, M., Thompson, S., & Ekhlaspour, L. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.08.009
Roadmap to Fully Closing the Loop to Optimize Health in Type 1 Diabetes
Marks, B. E., Hilliard, M. E., Kovatchev, B. P., Moser, O., Tanenbaum, M. L., Ackeifi, C. A., Ahn, D. T., Ajjan, R., Albanese-O’Neill, A., BAKHSH, A. M. K., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261496643
Self-citation
Metadata
- Authors
- Kovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A.
- Affiliations
- University of Virginia (US)
- Tandem Diabetes Care (United States) (US)
- 2Tandem Diabetes Care, San Diego, CA
- Corresponding author
- Kovatchev, Boris P.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-20
- Volume
- 45
- Issue
- 11
- Pages
- 2636-2643
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC9862393
- OpenAlex
- W4297874927
- Semantic Scholar
- 19eea3683df3e9d8cbaea7cbb17831fef0f35987
- Cited by
- 49
- References
- 28
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 15 · 2023: 8
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Virginia (Strategic Investment Fund Project #88)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- artificial pancreas, type 1 diabetes, predictive low glucose suspend, Control-IQ, continuous glucose monitoring, glycemic control, time in range, age differences, glucose management indicator
- MeSH terms
- Adolescent, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemic Agents, Insulin, Male, Blood Glucose Self-Monitoring, Insulin, Regular, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.